CSL Celebrates Remarkable Full-Year Profit Surge Driven by Innovation and Global Demand

Global biotechnology giant CSL Limited (ASX: CSL) today unveiled an impressive surge in its full-year net profit, signaling a period of robust growth and strategic success. The company reported a substantial 15% increase in net profit after tax, reaching $2.5 billion USD, driven by strong demand for its diverse portfolio of life-saving biotherapeutics and innovative vaccines.

This remarkable financial performance underscores CSL's unwavering commitment to addressing serious unmet medical needs worldwide.

Key drivers of this growth included exceptional sales of its core immunoglobulin therapies, essential for treating a range of autoimmune and neurological conditions, as well as continued expansion in its albumin and specialty product segments. The company's vaccine division, CSL Seqirus, also delivered stellar results, bolstered by strong influenza vaccine sales and advancements in its innovative vaccine pipeline.

Mr.

Paul Perreault, CEO and Managing Director of CSL, commented on the results: "Our outstanding full-year performance is a testament to the dedication of our global teams and the strength of our differentiated product portfolio. We continue to see robust demand for our plasma-derived therapies and vaccines, which are vital for patients in over 100 countries.

Our strategic investments in research and development are yielding promising results, setting the stage for future innovation and growth."

CSL's commitment to pioneering research and development remains a cornerstone of its strategy, with significant investments directed towards advancing its pipeline.

The company is actively progressing several clinical programs aimed at addressing critical medical challenges, including novel therapies for rare diseases and next-generation vaccines. This R&D focus ensures CSL remains at the forefront of medical innovation, consistently delivering breakthroughs that improve patient outcomes.

Geographically, CSL witnessed strong performance across all key markets, with particular strength observed in North America, Europe, and Asia Pacific.

The company's global supply chain and manufacturing capabilities proved resilient, ensuring consistent product availability to meet escalating patient demand, even amidst a complex global environment.

Looking ahead, CSL anticipates continued momentum, forecasting further growth in the upcoming fiscal year.

The company plans to maintain its strategic focus on expanding its plasma collection network, accelerating R&D initiatives, and exploring new market opportunities. CSL reiterates its mission to develop and deliver innovative biotherapies that help people with life-threatening medical conditions live full lives.